Pioglitazone in the treatment of NASH: the role of adiponectin (Articolo in rivista)

Type
Label
  • Pioglitazone in the treatment of NASH: the role of adiponectin (Articolo in rivista) (literal)
Anno
  • 2010-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1111/j.1365-2036.2010.04405.x (literal)
Alternative label
  • Gastaldelli, A.; Harrison, S.; Belfort-Aguiar, R.; Hardies, J.; Balas, B.; Schenker, S.; Cusi, K. (2010)
    Pioglitazone in the treatment of NASH: the role of adiponectin
    in Alimentary pharmacology & therapeutics; WILEY-BLACKWELL, MALDEN 02148,MA (Stati Uniti d'America)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Gastaldelli, A.; Harrison, S.; Belfort-Aguiar, R.; Hardies, J.; Balas, B.; Schenker, S.; Cusi, K. (literal)
Pagina inizio
  • 769 (literal)
Pagina fine
  • 775 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 32 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 7 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 6 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • [1,3,5,7] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78284 USA [1]CNR, Natl Res Council, Inst Clin Physiol, I-00185 Rome, Italy [2]Brooke Army Med Ctr, Div Gastroenterol, San Antonio, TX USA [4]Univ Texas Hlth Sci Ctr San Antonio, Dept Med & Radiol, San Antonio, TX 78284 USA [6] Univ Texas Hlth Sci Ctr San Antonio, Div Gastroenterol, San Antonio, TX 78284 USA [7]Brooke Army Med Ctr, Div Diabet, Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA (literal)
Titolo
  • Pioglitazone in the treatment of NASH: the role of adiponectin (literal)
Abstract
  • Background Plasma adiponectin is decreased in NASH patients and the mechanism(s) for histological improvement during thiazolidinedione treatment remain(s) poorly understood. Aim To evaluate the relationship between changes in plasma adiponectin following pioglitazone treatment and metabolic/histological improvement. Methods We measured in 47 NASH patients and 20 controls: (i) fasting glucose, insulin, FFA and adiponectin concentrations; (ii) hepatic fat content by magnetic resonance spectroscopy; and (iii) peripheral/hepatic insulin sensitivity (by double-tracer oral glucose tolerance test). Patients were then treated with pioglitazone (45 mg/day) or placebo and all measurements were repeated after 6 months. Results Patients with NASH had decreased plasma adiponectin levels independent of the presence of obesity. Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01-0.001 vs. placebo). In the pioglitazone group, plasma adiponectin was significantly associated (r = 0.52, P = 0.0001) with hepatic insulin sensitivity and with the change in both variables (r = 0.44, P = 0.03). Increase in adiponectin concentration was related also to histological improvement, in particular, to hepatic steatosis (r = -0.46, P = 0006) and necroinflammation (r = -0.56, P < 0.0001) but importantly also to fibrosis (r = -0.29, P = 0.03). Conclusions Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients. (literal)
Editore
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
Insieme di parole chiave di
data.CNR.it